| Retherapy with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. | |
| | |
MedLine Citation:
|
PMID: 23151046 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
ABSTRACT Bendamustine and bendamustine/rituximab-combinations have shown high efficacy in relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent B-cell-malignancies (NHL). No data do exist about bendamustine-retherapy after relapse concerning efficacy and toxicity in this patient population. 88 outpatients (57 patients with CLL, 31 patients with NHL) who previously had been treated with bendamustine were retreated with a bendamustine regimen. Treatment consisted of bendamustine (B) or bendamustine + mitoxantrone (BM) or bendamustine + rituximab (BR) or bendamustine + mitoxantrone + rituximab (BMR). Median age was 72 (50-88). A reversible grade 3 or 4 leukocytopenia or thrombocytopenia could be observed in 24% and 13% respectively. Overall response rate (ORR) was 76% (7% CR, 69% PR) with 77% (6% CR, 71% PR) in CLL and 71% (8% CR, 63% PR) in NHL. ORR according to regimen was as follows: B: 57% (14% CR, 43% PR), BM: 70% (4% CR, 66% PR), BR: 55% (10% CR, 45% PR), BMR: 84% (7% CR, 78% PR). Bendamustine retherapy is feasible and achieves high response rates and some long lasting remissions. |
| | |
Authors:
|
Rudolf Weide; Stefan Feiten; Vera Friesenhahn; Jochen Heymanns; Kristina Kleboth; Jörg Thomalla; Christoph van Roye; Hubert Köppler |
Related Documents
:
|
23417696 - A phase 2 multicenter study of tivantinib (arq 197) monotherapy in patients with relaps... 782696 - Nitrosoureas in the management of disseminated malignant melanoma. 16166076 - Use of antioxidants during chemotherapy and radiotherapy should be avoided. 18842536 - Bendamustine: a novel cytotoxic agent for hematologic malignancies. 17920916 - Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or redu... 9762946 - Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer c... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-14 |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: - ISSN: 1029-2403 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: MMpred: functional miRNA - mRNA interaction analyses by miRNA expression prediction.
Next Document: Red/green cyanobacteriochromes: sensors of color and power.